SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS drew attention after a sharp, high-volume selloff amid broader biotech weakness and options-expiration chatter. Traders debated whether the decline was market and options-driven or reflected concern over the prolonged wait for the REGAL Phase 3 80th-event update and topline data; bullish holders largely bought or held, while skeptics questioned managements silence and the trials uncertain outcome.

WorldFinancial

World Liberty Financials preliminary conditional approval to establish a national trust bank for its USD1 stablecoin is driving discussion, with bullish traders viewing the charter as a potential source of legitimacy and future utility for WLFI. Skeptics counter that the token has remained weak and question whether the development will benefit holders, amid broader concerns about Trump-family involvement and token monetization.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. The firm operates through the following geographical segments: United States and International. It offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Lingering concerns about weak revenue guidance, advertising-market growth and competitive pressure are weighing on TTD, while repeated failed rallies have fueled criticism of CEO Jeff Green and company execution. Bulls argue the selloff is excessive and point to high short interest as potential fuel for a rebound, but a squeeze remains speculation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a sharp selloff across AI infrastructure and neocloud stocks, as concern over CoreWeaves debt and rising financing costs fuels doubts about the sectors capital-heavy business model; traders also point to broader weakness in AI and technology shares. The community is divided between seeing the drop as a sector-wide valuation reset with further downside risk and viewing Nebiuss comparatively stronger balance sheet and AI demand outlook as reasons to buy the dip.

XYO is the cryptographic proof layer for the real world, collecting, validating, and delivering physical-world data to AI, robotics, Web3, and enterprise systems. XYO, the original Decentralized Physical Infrastructure Network (DePIN), has been operating since 2018 and now has more than 10 million nodes worldwide.   At the core of XYO is XYO Layer One, a scalable data blockchain built to support high-volume data industries such as AI, robotics, location intelligence, and real-world asset (RWA) systems. Designed for high throughput and low transaction costs, it gives these data-intensive applications the capacity to process and validate information across massive datasets. XYO Layer One anchors XYO's Proof of Location and Proof of Origin technologies, establishing a verified origin, precise timing, and trusted source behind every piece of data. This verified data directly feeds the XYO AI SDK, a product built by XYO to provide accessibility for developers to build AI-powered applications, autonomous agents, robotics integrations and more using real-world data.  XYO employs a unique dual-token model:  XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases.  The dual-token economics are strategically designed to increase scarcity and promote sustainable growth.   The XYO token has been available on major exchanges since 2018. Major exchanges include Coinbase and Revolut. The XL1 token is now also available.

XYO Network

XYO is drawing attention for its volatile price action and repeated rallies that traders say quickly fade, with complaints about weak volume and difficulty holding gains. Bulls are accumulating and speculate about future AI/DePIN utility or partnerships, while skeptics view the moves as pump-and-dump behavior.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is drawing attention amid a sharp decline and trader concerns about an Upbit delisting, with debate over whether the exchange news signals deeper trouble or creates a buying opportunity. Some holders point to JasmyChain and partnership developments as longer-term reasons for optimism, while skeptics question adoption and the tokens performance.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is being tied to concerns about its debt-heavy AI data-center expansion, rising borrowing costs and the risk that future returns may not justify the investment, amid broader weakness in AI and semiconductor stocks. Bearish traders warn of refinancing pressure and potential distress, while dip buyers point to AI demand, contracted capacity and Nvidias support as reasons the decline may be overdone.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

BEs steep, volatile pullback is being linked to a broader selloff in AI and growth stocks, with traders citing inflation, rates, oil, and uncertainty about AI spending; claims of forced selling or coordinated shorting remain speculation. The debate is heightened by upcoming earnings: bulls are buying dips on data-center power demand and Blooms AEP/Google and Oracle projects, while bears question the valuation and whether results can meet expectations.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake shares are under pressure amid uncertainty over FDA review of its submitted sonelokimab application for hidradenitis suppurativa, with traders also questioning the drugs differentiation after disappointing IZAR-1 results and managements plan to commercialize independently. Bearish posts warn of approval risk, commercial costs and possible dilution, while bullish holders argue the pipeline remains promising and the selloff reflects broader biotech weakness.

Costco Wholesale Corp. engages in the provision of operation of membership warehouses through wholly owned subsidiaries. It operates through the following geographical segments: United States, Canada, and Other International Operations. The company was founded by James D. Sinegal and Jeffrey H. Brotman in 1983 and is headquartered in Issaquah, WA.

Costco Wholesale Corp

Strong September comparable-sales growth and bullish analyst commentary have renewed interest in Costco, with traders cheering the stocks breakout and arguing it could keep climbing. Others question its premium valuation and point to slower membership-fee growth and competition for investor attention from technology stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The pullback appears tied to broader market and biotech weakness, with traders also citing options expiry and uncertainty ahead of the FDA decision on deramiocel for Duchenne muscular dystrophy, scheduled for November 22, 2026.

CAPR Stock Rises Nearly 5% As Capricor Presents Heart Data For Deramiocel Ahead Of November FDA Decision

Equity

Craig McDonald said on Wednesday that in patients in the HOPE-3 trial with weakened hearts, Deramiocel treatment produced “essentially complete stabilization” over a year. 


Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November

Capricor’s Phase 3 HOPE-3 open-label extension data shows significant improvement in upper limb decline, but H.C. Wainwright said it did not remove the statistical uncertainty from the original trial.

CAPR Stock Clocks Best Day In Over A Month As 24-Month Duchenne Data Airs At Medical Conference In Japan

The company is slated to orally present long-term trial results of deramiocel at the World Muscle Society congress in Hiroshima on October 3.


Capricor Therapeutics Stock Surges: What's Going On?

Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are trading higher Wednesday morning following the release of positive long-term clinical data for its lead cellular therapy. read more...

Shredding Pounds, Trading Stocks—Lilly’s Potential Obesity Blockbuster and other Biotechs in Play

The biotech tape is entering a catalyst-heavy stretch, with NeOnc Technologies Holdings (NASDAQ:NTHI), Connect Biopharma (NASDAQ:CNTB), Valion Bio (NASDAQ:VBIO), Eli Lilly and Company (NYSE:LLY), Celcuity (NASDAQ:CELC), and Capricor Therapeutics (NASDAQ:CAPR) heading into important stretches, but for very different reasons.

Why Are Nasdaq Futures Rising Premarket? MU, TSLA, CAPR, VNDA, ASTS, HOOD, BA Stocks In Focus

On Stocktwits, retail sentiment toward SPY and QQQ stayed ‘bullish.’ 


Dow, S&P 500, Nasdaq Futures Mixed As 30-Year Yield Climbs Higher: CAPR, IOVA, DKNG, TTD In Focus

The 30-year Treasury yield topped 5.6% on Tuesday, its highest in more than 24 years, while New York Fed President John Williams said there's no "urgency" to raise rates.

Why Did CAPR Stock Jump 20% After-Hours Today?

Patients switching from placebo to Deramiocel recorded 76% slower upper-limb decline and 66% slower decline in elbow-related function.

CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Capricor Therapeutics, Inc. (Capricor or the Company) (NASDAQ: CAPR) and reminds investors of the September 28, 2026 deadline to seek the role of lead plaintiff in a federal securities class...

CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline

CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Bullish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

Investors are closely monitoring the upcoming November 22 FDA decision, betting on potential drug approval despite market volatility.

Optimism is rising that the FDA’s new flexible regulatory framework for rare diseases could favor current pipeline data.

Bulls are pointing to heavy short interest and limited float as primary catalysts for an explosive move higher upon positive news.

Traders are navigating intraday swings and price manipulation, urging others to hold strong against perceived institutional shakeouts.

Current Price	$6.71
Prev Close	$7.27
Open	$7.21
Dividend Yield	0.00%
50-Day Moving Average	$7.94
Beta	1.06
Avg. Volume	3.85M
PE Ratio	-2.74

52-Week High	$40.37
52-Week Low	$2.96
Market Capitalization	$422.67M
EPS (Annual)	-$2.26
Price to Book	1.58
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CAPR Fundamentals